Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.60    -0.05 (-0.40%)
Bid:
12.60
Ask:
12.95
Spread: 0.35 (2.778%)
Market Cap: £42.85m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

Dividend Declaration

4 Jan 2022 07:00

RNS Number : 2467X
BATM Advanced Communications Ld
04 January 2022
 

LEI: 213800FLQUB9J289RU66

4 January 2022

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Dividend Declaration

Further to the Group's announcement of 14 December 2021, BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, gives notice of how eligible shareholders who are not Israeli tax residents can apply for, and benefit from, a reduced withholding tax rate with regards to the dividend payment.

 

Withholding Tax Rate

 

In accordance with Israeli tax regulation, the Group will withhold at source 16.74% (the "Withholding Tax Rate") of the gross amount of the dividend. Shareholders or holders of depositary interests in respect of ordinary shares in the Company who are subject to a lower withholding tax rate as a resident of a country with which Israel has a treaty for the avoidance of double taxation, such as the UK, may be eligible to benefit from a reduced withholding tax rate ("Eligible Shareholder").

 

Under the Double Taxation Treaty between Israel and the UK, a shareholder or depositary interest holder who is a British tax resident (and does not have a permanent establishment in Israel) and whose dividend income is subject to tax in the UK, is entitled to a reduced withholding tax rate of 15.00% or 5.00% if the beneficial owner of the dividend is a company (the "Reduced Withholding Tax Rate").

 

Dividend Payment Process and Applying for Reduced Withholding Tax Rate

 

The Group has appointed IBI Trust Management as its trustee and sub-paying agent (the "Tax Trustee"). The Group will transfer 16.74% of the gross amount of the dividend to the Tax Trustee and the remaining balance will be paid to shareholders or depositary interest holders through Link Group or a shareholder's relevant broker.

 

Eligible Shareholders can apply to the Tax Trustee to reclaim the difference between the amount withheld in accordance with the Withholding Tax Rate and the amount that would be withheld if the Reduced Withholding Tax Rate (or equivalent rate for Eligible Shareholders in jurisdictions other than the UK) were applied.

 

To apply for a reduced withholding tax rate, Eligible Shareholders must deliver to the Tax Trustee, via the email address below, scanned copies of specified tax residency and banking documentation and a completed application form (the "Application") by 15 February 2022 (the "Application Deadline"). The documents required to be included in the Application are detailed in the application form, which is available for download at the following link or by contacting the Tax Trustee:

 

https://www.batm.com/media/1486/tax-withholding-form.pdf

 

The Tax Trustee will review the Applications and refund to Eligible Shareholders, who submitted approved and complete Applications by the Application Deadline, any excess tax withheld in accordance with any applicable reduced withholding tax rate. Following the repayments of such refunds, the Tax Trustee will remit all remaining funds to the Israel Tax Authority.

 

Tax Trustee Contact Information

 

The contact information for the Tax Trustee, including the email address for submitting Applications, is as follows:

 

IBI Trust Management

Address: 9 Ehad Ha'am (Shalom Tower), Tel Aviv, Israel

Email: IBI-CM@IBI.co.il 

Phone: +972 506 209 410

 

 

Shareholders are advised to consult with their own personal tax and financial advisers as to the tax consequences resulting from their personal tax situation.

 

 

Enquiries:

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

Shore Capital

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 20 7408 4050 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVUPURPGUPPGAW
Date   Source Headline
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM
17th Mar 202210:30 amRNSResult of General Meeting
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 202211:30 amRNSHolding(s) in Company
28th Feb 20227:00 amRNSFull Year Results
23rd Feb 20227:00 amRNSNotice of General Meeting
21st Feb 20227:00 amRNSStrategic Partnership for Edgility with Advantech
17th Feb 20227:00 amRNSTrading Update and Notice of Results
3rd Feb 202211:23 amRNSClarification on FTSE Nationality Review
3rd Feb 20227:00 amRNSUpdate on FTSE Nationality Review & Share Buyback
31st Jan 20227:00 amRNSUpdate on Ador Diagnostics
17th Jan 20227:00 amRNSUpdate on FTSE Nationality Review
4th Jan 20227:00 amRNSDividend Declaration
4th Jan 20227:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSFirst sales of rapid COVID-19 test in Russia
14th Dec 202111:45 amRNSResult of AGM and Dividend Declaration
30th Nov 20217:00 amRNSCOVID-19 tests effective in diagnosing Omicron
25th Nov 20213:00 pmRNSBlock Listing Interim Review
22nd Nov 20213:00 pmRNSNotice of AGM and Dividend Declaration
10th Nov 20217:00 amRNSBATM receives $3.5m cyber security contract
3rd Nov 20217:00 amRNSNew five-year contract for Edgility
1st Nov 20217:00 amRNSBATM receives agri-waste contract in Botswana
7th Oct 20217:00 amRNSStrategic partnership for NFV with AudioCodes
13th Sep 20217:00 amRNSFirst enterprise customer for NFV with $2m order
23rd Aug 20217:00 amRNSInterim Results
12th Aug 20217:00 amRNSNotice of Results
12th Jul 20217:00 amRNSLaunch of Edgility networking NFV-based ecosystem
5th Jul 20217:00 amRNSBATM receives $10m cyber security contract
15th Jun 20217:00 amRNSBATM receives $4.1m cyber security contract
26th May 20217:00 amRNSBlock listing Interim Review
18th May 20217:00 amRNSBATM commences delivery of new COVID-19 tests
19th Apr 202110:25 amRNSAnnual Financial Report
12th Apr 20217:00 amRNSStrategic partnership for NFV
29th Mar 20217:00 amRNSBATM develops molecular diagnostics test for TB
19th Mar 20217:00 amRNSCompletion of Sale of NGSoft
11th Mar 20217:00 amRNSBATM launches no-swab saliva-based COVID-19 test
1st Mar 20217:00 amRNSUpdate on Sale of NGSoft
22nd Feb 20217:00 amRNSFull Year Results
11th Feb 20215:38 pmRNSFTSE Nationality Review
1st Feb 20217:00 amRNSTrading Update and Notice of Results
19th Jan 20217:00 amRNSBATM's NFVTime now available for the public cloud
12th Jan 20217:00 amRNSBATM enters option agreement to sell NGSoft
24th Dec 20207:00 amRNSCOVID-19 test effective in diagnosing new strain
17th Dec 20203:50 pmRNSResult of AGM
15th Dec 20207:00 amRNSUpdate on Ador Diagnostics
7th Dec 20207:00 amRNSDelivery of First Insect Protein Recovery Facility
30th Nov 20203:03 pmRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.